(photo: )

ABIVAX discovers novel antiviral molecules to tackle Dengue

ABIVAX, a biotech company targeting the immune system to eliminate viral diseases, is currently screening its targeted library of small molecules to discover and develop antiviral therapeutic candidates against dengue fever.




  •  (photo: )

    Pharmaceutical growth continues to set technology pace

    While food and beverage remain the largest sectors in terms of packaging machinery needs, no market can keep pace with the pharmaceutical growth forecast through 2020, according to the 2016 State of the Industry US Packaging Machinery Report.




 (photo: )

ABPI welcomes Prime Minister’s speech negotiating Brexit

The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), has welcomed the Prime Minister’s speech on the Government’s negotiating objectives for exiting the EU.

 (photo: )

EMA revising guideline on first-in-human clinical trials

The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union, is proposing changes to its existing guideline on first-in-human clinical trials, to further improve the safety of trial participants.


 (photo: )

Sobi enters new distribution agreement with Valeant for Ammonul

Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul injection in Europe, the Middle East and North Africa.

 (photo: )

Yorkshire pharma startup ships first medicines to Iraq

The first consignment of British manufactured medicines has been exported to Iraq by a new Yorkshire pharmaceuticals wholesaler and distributor set up to give Iraqi people access to high-quality treatments.


 (photo: )

Valeant Pharma & EyeGate enter agreement for eye pain relief

EyeGate has granted a subsidiary of Valeant Pharmaceuticals exclusive worldwide commercially and manufacturing rights to its EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.

 (photo: )

Novartis gains Priority Review for lung cancer treatment

The US Food and Drug Administration (FDA) has accepted Novartis’ supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.